MA51897A - Procédés d'utilisation de dérivés de benzotriazole trisubstitués - Google Patents

Procédés d'utilisation de dérivés de benzotriazole trisubstitués

Info

Publication number
MA51897A
MA51897A MA051897A MA51897A MA51897A MA 51897 A MA51897 A MA 51897A MA 051897 A MA051897 A MA 051897A MA 51897 A MA51897 A MA 51897A MA 51897 A MA51897 A MA 51897A
Authority
MA
Morocco
Prior art keywords
methods
benzotriazole derivatives
trisubstituted benzotriazole
trisubstituted
derivatives
Prior art date
Application number
MA051897A
Other languages
English (en)
French (fr)
Inventor
Sung Eun Choe
Danielle Ulanet
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MA51897A publication Critical patent/MA51897A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051897A 2018-02-20 2019-02-19 Procédés d'utilisation de dérivés de benzotriazole trisubstitués MA51897A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20

Publications (1)

Publication Number Publication Date
MA51897A true MA51897A (fr) 2020-12-30

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051897A MA51897A (fr) 2018-02-20 2019-02-19 Procédés d'utilisation de dérivés de benzotriazole trisubstitués

Country Status (13)

Country Link
US (2) US11717512B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755324B1 (cg-RX-API-DMAC7.html)
JP (2) JP7434185B2 (cg-RX-API-DMAC7.html)
KR (1) KR102861339B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757731B (cg-RX-API-DMAC7.html)
AU (1) AU2019223906B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016929A8 (cg-RX-API-DMAC7.html)
CA (1) CA3091792A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038736T3 (cg-RX-API-DMAC7.html)
MA (1) MA51897A (cg-RX-API-DMAC7.html)
MX (1) MX2020008678A (cg-RX-API-DMAC7.html)
TW (1) TWI818954B (cg-RX-API-DMAC7.html)
WO (1) WO2019164794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
AU7622000A (en) 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
NZ588896A (en) * 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101177729B1 (ko) 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) * 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
EP3858361B1 (en) 2018-09-28 2025-10-08 FUJIFILM Corporation Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
WO2020109625A1 (en) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
EP4034084B1 (en) 2019-09-27 2025-11-05 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
US20230285364A1 (en) 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Also Published As

Publication number Publication date
KR20200123137A (ko) 2020-10-28
US11717512B2 (en) 2023-08-08
CA3091792A1 (en) 2019-08-29
WO2019164794A1 (en) 2019-08-29
AU2019223906B2 (en) 2024-11-21
EP3755324A1 (en) 2020-12-30
EP3755324C0 (en) 2025-07-30
BR112020016929A2 (pt) 2020-12-15
US12290508B2 (en) 2025-05-06
AU2019223906A1 (en) 2020-09-10
JP7434185B2 (ja) 2024-02-20
CN111757731A (zh) 2020-10-09
ES3038736T3 (en) 2025-10-14
TW201938543A (zh) 2019-10-01
CN111757731B (zh) 2024-06-25
KR102861339B1 (ko) 2025-09-19
JP2021514395A (ja) 2021-06-10
EP3755324B1 (en) 2025-07-30
JP2023109974A (ja) 2023-08-08
US20240148697A1 (en) 2024-05-09
TWI818954B (zh) 2023-10-21
US20210113531A1 (en) 2021-04-22
MX2020008678A (es) 2020-09-25
BR112020016929A8 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
EP3600318A4 (en) METHOD OF USING EHMT2 INHIBITORS
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EP3768671A4 (en) SUBSTITUTED IMIDAZOLIDIN-2-ON DERIVATIVES AS PRMT5 INHIBITORS
EP3704239A4 (en) CASZ COMPOSITIONS AND METHOD OF USE
EP3429635A4 (en) ANTI-CRISPR COMPOUNDS AND METHOD OF USE
EP3906029A4 (en) INHIBITORS OF MENIN-MLL INTERACTION
EP3359164A4 (en) COMPOUNDS AND METHOD FOR MODULATING ANGIOTENSINOGENEXPRESSION
EP3768267A4 (en) KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
EP3307271A4 (en) METHOD OF USE OF PYRUVATE KINASE ACTIVATORS
EP3519572A4 (en) CONNECTIONS AND METHOD FOR REDUCING TAU EXPRESSION
EP3688011A4 (en) PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
EP3443094A4 (en) PROCESS FOR REDUCING C9ORF72 EXPRESSION
EP3459323A4 (en) Spray chambers and methods of using them
EP3654987A4 (en) USE OF AMINOALKYLBENZOTHIACEPINE DERIVATIVES
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3458448A4 (en) METHOD OF USE OF FASN INHIBITORS
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3969460A4 (en) ASCAROSIDE DERIVATIVES AND METHODS OF USE
EP3468555A4 (en) ANTIMICROBIAL CONNECTIONS AND METHOD FOR USE THEREOF
EP3307254A4 (en) MITO-HONOKIOL COMPOUNDS AND METHOD FOR SYNTHESIS AND USE THEREOF
EP3426349A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
EP3402443A4 (en) DEVICES AND COMPOSITIONS AND METHODS FOR USE THEREOF
EP3302488A4 (en) NOVEL USE OF ARYLCHINOLINE DERIVATIVES AS INHIBITORS OF VASCULAR MIMICRY
EP4043450A4 (en) 2h-benzopyran derivatives as crac inhibitors
MA52722A (fr) Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation